Klaus Rose

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 10

Top Venues

Pharmaceutical medicine

Expert review of neurotherapeutics

Journal of clinical pharmacology

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

klausrose Consulting

Technische Universität Berlin (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

klausrose Consulting

Switzerland

CEO

Granzer Regulatory Consultancy

Germany

Principal Consultant

F Hoffman La Roche Ltd

Switzerland

Global Head Pediatrics :: Development

Novartis Pharma AG

Switzerland

Global Head Pediatrics :: Development

Novartis Pharma AG

Switzerland

Senior International Medical Advisor :: Clinical Research & Development

Novartis

Switzerland

Clinical Research Physician

Byk Gulden Pharma

Germany

Clinical Research Physician :: Clinical Research & Development

Byk Gulden Pharma Switzerland

Switzerland

Medical Director

Education History

Technische Universität Berlin

Germany

MSC

Publications

Earl B Ettienne, Jane M Grant-Kels, Pasquale Striano, Emilio Russo, David Neubauer, Klaus Rose
Pharmacogenomics and pediatric drug development: science and political power. A narrative review. Expert opinion on pharmacotherapy (2024)
Gianluca D'Onofrio, Antonella Riva, Elisabetta Amadori, Simona Lattanzi, Klaus Rose, Alberto Verrotti, Pasquale Striano
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overview. Expert opinion on drug metabolism & toxicology 18 (9) (2022)
Klaus Rose, Earl B Ettienne, Jane M Grant-Kels, Pasquale Striano, David Neubauer, Oishi Tanjinatus
Neurology's vital role in preventing unnecessary and potentially harmful pediatric studies. Expert review of neurotherapeutics 22 (3) (2022)
Klaus Rose
Paediatric Oncology at the Crossroads: A Call for Change. Pharmaceutical medicine 34 (5) (2021)
Klaus Rose, Oishi Tanjinatus, Earl B Ettienne
The Term "Juvenile Idiopathic Arthritis (JIA)" is Misleading. It Will not be Sufficient to Just Replace this Term. Pharmaceutical medicine 35 (3) (2021)
Klaus Rose, Jane M Grant-Kels, Pasquale Striano, David Neubauer, Oishi Tanjinatus, Earl B Etienne
Warp speed for COVID-19 drugs and vaccines - time to re-consider how we use the term 'children'. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Klaus Rose, Oishi Tanjinatus, Jane M Grant-Kels, Earl B Ettienne, Pasquale Striano, David Neubauer
Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development. Journal of clinical pharmacology 61 (6) (2021)
Klaus Rose, Jane M Grant-Kels, Earl B Ettienne, Oishi Tanjinatus, Pasquale Striano, David Neubauer
Comment on: A review of the experience with pediatric written requests issued for oncology drug products. Pediatric blood & cancer 68 (8) (2021)
Klaus Rose, Jane M Grant-Kels
The Meanings of "Pediatric Drug Development". Therapeutic innovation & regulatory science 53 (6) (2018)
Klaus Rose, Philip D Walson
Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare? Paediatric drugs 19 (6) (2017)

Klaus Rose.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Klaus Rose